Renaissance Capital logo

Twist Bioscience Priced, Nasdaq: TWST

Manufactures synthetic genes and other DNA-based products.

Industry: Health Care

First Day Return: 0.0%

Industry: Health Care

We are a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than our competitors. We are leveraging our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sample preparation, and antibody libraries for drug discovery and development. Additionally, we believe our platform will enable new value-add opportunities, such as discovery partnerships for biologic drugs, and will enable new applications for synthetic DNA, such as digital data storage. We sell our synthetic DNA and synthetic DNA-based products to a customer base of over 600 customers across a broad range of industries.
more less
IPO Data
IPO File Date 10/03/2018
Offer Price $14.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/30/2018
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $70
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters San Francisco, CA, United States
Founded 2013
Employees at IPO 221
Website www.twistbioscience.com

Twist Bioscience (TWST) Performance